You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

DELZICOL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Delzicol, and when can generic versions of Delzicol launch?

Delzicol is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in DELZICOL is mesalamine. There are twenty-eight drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Delzicol

A generic version of DELZICOL was approved as mesalamine by PADAGIS ISRAEL on September 17th, 2004.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DELZICOL?
  • What are the global sales for DELZICOL?
  • What is Average Wholesale Price for DELZICOL?
Drug patent expirations by year for DELZICOL
Drug Prices for DELZICOL

See drug prices for DELZICOL

Drug Sales Revenue Trends for DELZICOL

See drug sales revenues for DELZICOL

Recent Clinical Trials for DELZICOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AbbViePhase 3
Holy Stone Healthcare Co., LtdPhase 1

See all DELZICOL clinical trials

Pharmacology for DELZICOL
Drug ClassAminosalicylate
Paragraph IV (Patent) Challenges for DELZICOL
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
DELZICOL Delayed-release Capsules mesalamine 400 mg 204412 1 2014-06-17

US Patents and Regulatory Information for DELZICOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie DELZICOL mesalamine CAPSULE, DELAYED RELEASE;ORAL 204412-001 Feb 1, 2013 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DELZICOL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie DELZICOL mesalamine CAPSULE, DELAYED RELEASE;ORAL 204412-001 Feb 1, 2013 ⤷  Sign Up ⤷  Sign Up
Abbvie DELZICOL mesalamine CAPSULE, DELAYED RELEASE;ORAL 204412-001 Feb 1, 2013 ⤷  Sign Up ⤷  Sign Up
Abbvie DELZICOL mesalamine CAPSULE, DELAYED RELEASE;ORAL 204412-001 Feb 1, 2013 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for DELZICOL

See the table below for patents covering DELZICOL around the world.

Country Patent Number Title Estimated Expiration
United Kingdom 8322387 ⤷  Sign Up
Italy 1149328 COMPOSIZIONE FARMACEUTICA PER LA SOMMINISTRAZIONE PER VIA ORALE DI COMPOSTI CHE DEBBONO ESSERE ASSORBITI NELL'INTESTINO CRASSO ⤷  Sign Up
Canada 1172570 COMPOSES PHARMACEUTIQUES ADMINISTRES PAR VOIE ORALE (ORALLY ADMINISTRABLE PHARMACEUTICAL COMPOSITIONS) ⤷  Sign Up
Finland 85216 ⤷  Sign Up
South Korea 100536084 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.